Published in BMJ on December 01, 2001
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med (2005) 3.13
Gene therapy for cancer treatment: past, present and future. Clin Med Res (2006) 1.30
Adoptive cellular immunotherapy in metastatic renal cell carcinoma: a systematic review and meta-analysis. PLoS One (2013) 0.84
Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact. Br J Cancer (2009) 0.79
Trends in cancer immunotherapy. Clin Med Insights Oncol (2010) 0.75
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 6.73
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science (1997) 4.58
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol (1996) 3.11
Retracted Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med (2000) 2.64
Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood (2000) 1.94
In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res (1995) 1.76
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res (1997) 1.58
Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol (1999) 1.15
Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol (1996) 1.01
Aldesleukin (recombinant interleukin-2): a review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma. BioDrugs (1997) 0.87
Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann N Y Acad Sci (1993) 0.81
Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor vaccine. Anticancer Res (1997) 0.81
Structure of human factor VIII. Nature (1984) 3.29
Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry (1986) 2.77
Influence of the codon following the AUG initiation codon on the expression of a modified lacZ gene in Escherichia coli. EMBO J (1987) 2.46
Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry (1986) 2.14
Percutaneous ostomy dilation: a technique for dilating the closed percutaneous endoscopic gastrostomy sites and reinserting gastrostomies. Gastrointest Endosc (1989) 1.54
The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem J (1992) 1.49
In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood (1994) 1.26
Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. J Biol Chem (1994) 1.23
Ca2+ responses in cytomegalovirus-infected fibroblasts of human origin. Virology (1987) 1.18
Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol (1998) 1.04
Streptomyces viridochromogenes spore germination initiated by calcium ions. J Bacteriol (1980) 1.03
Human platelets as a model for the binding and degradation of thrombopoietin. Blood (1997) 0.95
Biochemical characterization of matrilysin. Activation conforms to the stepwise mechanisms proposed for other matrix metalloproteinases. Biochemistry (1992) 0.88
A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. Br J Cancer (2009) 0.86
Calcified neonatal renal vein thrombosis demonstration by CT and US. Pediatr Radiol (1990) 0.85
Cimetidine in colorectal cancer--are the effects immunological or adhesion-mediated? Br J Cancer (2002) 0.83
Organophosphate pesticide exposure in a group of Washington State orchard applicators. Environ Res (1992) 0.82
An agonist murine monoclonal antibody to the human c-Mpl receptor stimulates megakaryocytopoiesis. Blood (1998) 0.81
Participation of patients with gynecological cancer in phase I clinical trials: two years experience in a major cancer center. Gynecol Oncol (2006) 0.81
Discovery of thrombin activatable fibrinolysis inhibitor (TAFI). J Thromb Haemost (2006) 0.80
A randomized, controlled trial of acupuncture self-needling as maintenance therapy for cancer-related fatigue after therapist-delivered acupuncture. Ann Oncol (2013) 0.80
Megakaryocytic differentiation of HIMeg-1 cells induced by interferon gamma and tumour necrosis factor alpha but not by thrombopoietin. Cytokine (1998) 0.79
Interactive Methods for Teaching Action Potentials, an Example of Teaching Innovation from Neuroscience Postdoctoral Fellows in the Fellowships in Research and Science Teaching (FIRST) Program. J Undergrad Neurosci Educ (2009) 0.77
Differential effect of cyanohydroxybutene on glutathione synthesis in liver and pancreas of male rats. Toxicol Appl Pharmacol (1993) 0.77
Augmentation of blood platelet levels by intratracheal administration of an adenovirus vector encoding human thrombopoietin cDNA. Nat Biotechnol (1997) 0.75
Use of phage display for the generation of human antibodies that neutralize factor IXa function. Blood Coagul Fibrinolysis (2000) 0.75
Cloned factor VIII and the molecular genetics of hemophilia. Cold Spring Harb Symp Quant Biol (1986) 0.75
Prospects for gene therapy using haemopoietic stem cells. Best Pract Res Clin Haematol (2001) 0.75
Development, ethics, and prenatal health outcomes. J Soc Philos (2000) 0.75
Intensity-modulated radiotherapy plan optimisation for skull base lesions: practical class solutions for dose escalation. Clin Oncol (R Coll Radiol) (2010) 0.75
Sterile services--who rules? J Sterile Serv Manage (1987) 0.75
Group purchasing trends in USA. Health Soc Serv J (1981) 0.75
Responses of seventh grade students to "do you have a partner with whom you would like to have a baby?". Psychol Rep (2000) 0.75
Purification of a hybrid plasminogen activator protein. J Chromatogr (1991) 0.75
Venous infarction of a testicle following factor IX concentrate (DEFIX) Br J Haematol (1998) 0.75
The use of gonadotropin-releasing hormone agonist to regulate oocyte retrieval time. Fertil Steril (1990) 0.75